Yet here we are, nearly two centuries later, using it as the single most important number in determining whether someone can access the most effective weight loss medications ever developed
For instance, on December 2, 2024, the American Diabetes Association (ADA) released a guidance statement on the use of compounded GLP-1 RA (glucagon-like peptide-1 receptor agonist) and dual GIP/GLP-1 RA (glucose-dependent insulinotropic polypeptide and GLP-1 RA) medication classes
Although activation of the GLP-1 receptor primarily facilitates weight reduction through appetite suppression, the inclusion of GIP receptor agonism offers supplementary and synergistic advantages, including improved insulin sensitivity and overall metabolic health
Rather than driving dramatic weight loss microdosing serves as a precision tool which is why it appeals to people who already take their training seriously
In 2024, many plans moved to offset spend from an expected jump in claims
It contains the same active ingredients as Ozempic and Wegovy (semaglutide), but its a daily tablet rather than a weekly injection